EMP develops systemic radiotherapy products based on its clinically proven c-Met targeting platform

Specific tumour uptake has been demonstrated in patients with gastric cancer, adenocarcinoma, renal cell carcinoma and lung carcinoma.


An independent clinical study with [68 Ga] EMP-100 concludes that:

"Visualization of c-MET expression with 68Ga-EMP-100 PET imaging allows for clinicopathological staging in mRCC and has potential as a predictive biomarker of targeted therapies."


Clinical phase 0 results indicate that [177Lu] EMP-100 could be effective in combination with immuncheckpoint inhibitors (ICIs) or PARP inhibitors (PARPi).


Unlike conventional c-Met targeted therapies EMP’s agents bind outside of the c-Met receptors active site and hence do not affect the c-Met pathway, thus by-passing typical c-Met targeted therapy safety issues.


The EMP peptide has been used in more than 100 patients without SAEs (in the form of EMI-137, a fluorescent optical imaging agent, which passed sucessfully phase 2a/b in CRC). EMP-10X agents build on the same peptide, but are dosed in a 1.000 fold lower concentration. Hence, not surprising, no adverse events have been observed in the 20 patients exposed to EMP-100 so far. Furthermore, NL authorities have confirmed that the pre-clinical safety/toxicology package of the theranostic 68Ga/177Lu pair of our lead compound EMP-100 is sufficient for clinical development through to MAA submission.


GMP production of EMP-100 is underway for the upcoming NSCLC and mRCC phase2 studies in France and in Germany/US, respectively.